HIGHLIGHTS
- who: Mona Teng from the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada have published the article: Pioneer of prostate cancer: past, present and the future of FOXA1, in the Journal: (JOURNAL)
- what: Recent functional characterization of FOXA1 mutants shed light on their complex modes of action in driving prostate cancer where the function may be divergent depending on the residues affected.
- future: Considering the prevalence and differential FOXA1 activity conferred by specific FOXA1 mutations future studies may consider conducting inhibition-screens with FOXA1 mutant model systems. Based on the varying function . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.